Levovanox (Vancomycin)

Vancomycin binds to the D‑Ala‑D‑Ala terminus of peptidoglycan precursors, blocking the cross‑linking of bacterial cell wall components. This inhibition disrupts cell wall synthesis, leading to bacterial lysis and death, particularly against Gram‑positive organisms.

The dosage of Levovanox is determined by the prescribing clinician based on infection type, severity, patient weight, renal function, and therapeutic drug monitoring. Specific dosing regimens are individualized and should follow local clinical guidelines.

Levovanox is classified as Pregnancy Category C, indicating that it should be used only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; a healthcare professional should evaluate the risk‑benefit ratio before use.

To order Levovanox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Levovanox (vancomycin) is a first‑line glycopeptide antibiotic for MRSA, offering bactericidal activity against resistant Gram‑positive bacteria. Alternatives such as linezolid or daptomycin may be used based on infection site, patient tolerance, and resistance patterns, but vancomycin remains a widely accepted standard in many clinical protocols.

Levovanox should be stored below 25°C in its original packaging, protected from moisture and light. Reconstituted solutions must be used promptly or stored according to the manufacturer’s instructions, typically at refrigerated temperatures if stability data allow.

Levovanox is administered intravenously for systemic infections, with the powder reconstituted and diluted according to aseptic technique. For Clostridioides difficile colitis, an oral formulation is used, swallowed directly or mixed with a suitable vehicle as directed by the prescriber.

The most serious risks include nephrotoxicity, which can impair kidney function, and ototoxicity, which may cause hearing loss or balance disturbances. Red man syndrome, an infusion‑related reaction, and rare anaphylactic responses also require immediate medical attention.

Levovanox should be avoided in patients with a known hypersensitivity to vancomycin or other glycopeptide antibiotics. Caution is advised for individuals with pre‑existing renal impairment, hearing disorders, or those receiving concurrent nephrotoxic or ototoxic drugs.